ALC stock icon

Alcon
ALC

$93.37
1.67%

Market Cap: 46.1B

 

About: Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments: visioncare and surgical. Visioncare comprises contact lenses, lenscare solutions, and a suite of ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon controls one fourth of the U.S. contact lens market. Surgical comprises intraocular lenses, ophthalmic surgical equipment, and consumables used during surgeries. Its main products include Centurion, a phacoemulsification device used during cataract surgeries, and a portfolio of IOLs including PanOptix and Vivity. Alcon has one of the largest installed bases of eye surgical equipment in the world.

Employees: 25,315

0
Funds holding %
of 6,702 funds
0
Analysts bullish %
of 20 analysts
0
News positive %
of 5 articles

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

41% more call options, than puts

Call options by funds: $221M | Put options by funds: $157M

8% more capital invested

Capital invested by funds: $17.9B [Q4 2023] → $19.3B (+$1.36B) [Q1 2024]

0.16% more ownership

Funds ownership: 46.95% [Q4 2023] → 47.12% (+0.16%) [Q1 2024]

1% less funds holding

Funds holding: 595 [Q4 2023] → 591 (-4) [Q1 2024]

5% less first-time investments, than exits

New positions opened: 69 | Existing positions closed: 73

6% less repeat investments, than reductions

Existing positions increased: 190 | Existing positions reduced: 203

6% less funds holding in top 10

Funds holding in top 10: 16 [Q4 2023] → 15 (-1) [Q1 2024]

Research analyst outlook

20 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$85
9%
downside
Avg. target
$97
3%
upside
High target
$105
12%
upside

20 analyst ratings

19 positive
95%
neutral
5%
negative
0%
BTIG
Ryan Zimmerman
3%upside
$96
Buy
Maintained
15 Jul 2024
Morgan Stanley
Patrick Wood
9%downside
$85
Equal-Weight
Upgraded
15 Jul 2024
Needham
David Saxon
8%upside
$101
Buy
Reiterated
12 Jul 2024
Wells Fargo
Larry Biegelsen
1%upside
$94
Overweight
Maintained
15 May 2024
Oppenheimer
Steven Lichtman
10%upside
$103
Outperform
Upgraded
15 May 2024

Financial journalist opinion

Based on 5 articles about ALC published over the past 30 days